Talis Biomedical Corp
NASDAQ:TLIS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
W
|
Western Superconducting Technologies Co Ltd
SSE:688122
|
CN |
|
Golf Digest Online Inc
TSE:3319
|
JP |
Talis Biomedical Corp
EPS (Diluted)
Talis Biomedical Corp
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
Talis Biomedical Corp
NASDAQ:TLIS
|
EPS (Diluted)
-$34
|
CAGR 3-Years
16%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
EPS (Diluted)
$1
|
CAGR 3-Years
63%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
EPS (Diluted)
$1
|
CAGR 3-Years
-9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Stryker Corp
NYSE:SYK
|
EPS (Diluted)
$8
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
8%
|
|
|
Abbott Laboratories
NYSE:ABT
|
EPS (Diluted)
$3
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
EPS (Diluted)
$7
|
CAGR 3-Years
29%
|
CAGR 5-Years
22%
|
CAGR 10-Years
16%
|
|
Talis Biomedical Corp
Glance View
Talis Biomedical Corp. develops and commercialize innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company is headquartered in Menlo Park, California. The company went IPO on 2021-02-12. (Talis) Is engaged in developing molecular diagnostic tests for infectious diseases at the point of care. The firm is focused on developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions. Talis is developing the Talis One platform, a cloud-enabled molecular diagnostic platform. The Talis One platform comprises a compact instrument, single-use test cartridges and software, including a central cloud database, which work together and are designed to provide central laboratory levels of accuracy. The platform is designed for use in non-laboratory settings, such as physicians’ offices, hospital emergency departments, urgent care clinics, ambulatory surgery centers, assisted living facilities, and cancer treatment and dialysis centers. The firm is also developing Talis One tests for respiratory infections, infections related to women’s health and sexually transmitted infections.
See Also
What is Talis Biomedical Corp's EPS (Diluted)?
EPS (Diluted)
-34.1
USD
Based on the financial report for Dec 31, 2023, Talis Biomedical Corp's EPS (Diluted) amounts to -34.1 USD.
What is Talis Biomedical Corp's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-20%
Over the last year, the EPS (Diluted) growth was 46%. The average annual EPS (Diluted) growth rates for Talis Biomedical Corp have been 16% over the past three years , -20% over the past five years .
